miRNA therapeutics to overcome current treatment challenges in oncology, and beyond
Cancer is a disease caused by multiple defects in a cell. Drugs blocking several tumorigenic signaling pathways at the same time may result in novel and better treatment strategies with higher efficacy, broader use, and less prone to drug-acquired resistance than drugs targeting a single target. miRNAs can inhibit multiple mRNA targets in a coordinated fashion, thereby regulating their translation into protein. By optimally using this characteristic of miRNAs, i.e., blocking activated cancer signaling pathways and preventing activation of alternative cancer signaling pathways, InteRNA designs breakthrough therapies tackling cancer.
miRNAs are naturally occurring, small non-coding double-stranded RNAs that trigger the RNA interference pathway. They result from an extensive processing route in which a long RNA transcript, folded in a hairpin structure, is cleaved into short strands of approximately ~22 nucleotides – the miRNA molecules.